Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors

Bioorganic & Medicinal Chemistry Letters
Bernard BarlaamBénédicte Delouvrié

Abstract

We report the discovery of a novel aminopyrazine series of PI3Kα inhibitors, designed by hybridizing two known scaffolds of PI3K inhibitors. We describe the progress achieved from the first compounds plagued with poor general kinase selectivity to compounds showing high selectivity for PI3Kα over PI3Kβ and excellent general kinase selectivity. This effort culminated with the identification of compound 5 displaying high potency and selectivity, and suitable physiochemical and pharmacokinetic properties for oral administration. In vivo, compound 5 showed good inhibition of tumour growth (86% tumour growth inhibition at 50mg/kg twice daily orally) in the MCF7 xenograft model in mice.

Citations

Mar 1, 2019·Biomolecules·Michelle S MillerSandra B Gabelli
Oct 4, 2019·European Journal of Medicinal Chemistry·Fatma M ElmenierKhaled A M Abouzid
Nov 22, 2019·ACS Medicinal Chemistry Letters·Gilles OuvryLaurent F Hennequin

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.